Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages

  Biganzoli, Laura ^a   Wildiers, Hans ^b   Oakman, Catherine ^a   Marotti, Lorenza ^c   Loibl, Sibylle ^d   Kunkler, Ian ^e   Reed, Malcolm ^f   Ciatto, Stefano ^g   Voogd, Adri C ^h   Brain, Etienne ⁱ   Cutuli, Bruno ^j   Terret, Catherine ^k   Gosney, Margot ^l   Aapro, Matti ^m   Audisio, Riccardo ⁿ  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c EUSOMA   (Italy)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g Mammography Screening Programme   (Italy)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ INSTITUT CURIE   (France)

^j Polyclinique de Courlancy ^*  (France)

^k CENTRE LÉON BÉRARD   (France)

^l UNIVERSITY OF READING   (United Kingdom)

^m CLINIQUE DE GENOLIER   (Switzerland)

ⁿ UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; FLUOROURACIL; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN;

BREAST CANCER; BREAST METASTASIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL PRACTICE; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; HORMONAL THERAPY; HUMAN; INTRADUCTAL CARCINOMA; MALE; MAMMOGRAPHY; MASTECTOMY; MEDICAL SOCIETY; MEDICAL SPECIALIST; PATIENT PREFERENCE; PRIORITY JOURNAL; REVIEW;

AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; DECISION MAKING; EUROPE; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84859140429     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70383-7     Document Type: Review

References (86)

1. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003, 21:3580-3587.
2. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8:1101-1115.
3. Hery C, Ferlay J, Boniol M, Autier P Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008, 19:1187-1194.
4. Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 2010, 28:2038-2045.
5. Anderson WF, Katki HA, Rosenberg PS Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 2011, 103:1397-1402.
6. de Munck L, Schaapveld M, Siesling S, et al. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Res Treat 2011, 129:229-233.
7. Wildiers H, Van Calster B, van de Poll-Franse LV, et al. Relationship between age and axillary lymph node involvement in women with breast cancer. J Clin Oncol 2009, 27:2931-2937.
8. Rosso S, Gondos A, Zanetti R, et al. Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 2010, 46:3351-3357.
9. Satariano WA, Ragland DR The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994, 120:104-110.
10. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:146-156.
11. Stotter A, Tahir M, Pretorius R, Robinson T Experiences of a multidisciplinary elderly breast cancer clinic: using the right specialists, in the same place, with time. Management of breast cancer in older women 2010, Springer, London. M. Reed, R. Audisio (Eds.).
12. Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 2010, 46:1502-1513.
13. Extermann M, Meyer J, McGinnis M, et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004, 49:69-75.
14. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002, 20:494-502.
15. Clough-Gorr KM, Stuck AE, Thwin SS, Silliman RA Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol 2010, 28:380-386.
16. Brain EG, Mertens C, Girre V, et al. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: a French Geriatric Oncology Group (GERICO) phase II multicentre trial. Crit Rev Oncol Hematol 2011, 80:160-170.
17. Girre V, Falcou MC, Gisselbrecht M, et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?. J Gerontol A Biol Sci Med Sci 2008, 63:724-730.
18. Audisio RA, Pope D, Ramesh HS, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008, 65:156-163.
19. Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011, 29:1290-1296.
20. Pallis AG, Wedding U, Lacombe D, Soubeyran P, Wildiers H Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?. Eur J Cancer 2010, 46:1019-1025.
21. Soubeyran P, Bellera C, Goyard J, et al. Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 9001.
22. Overcash JA, Beckstead J, Extermann M, Cobb S The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol 2005, 54:129-136.
23. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med 2009, 151:727-737.
24. Zappa M, Visioli CB, Ciatto S Mammography screening in elderly women: efficacy and cost-effectiveness. Crit Rev Oncol Hematol 2003, 46:235-239.
25. Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer 2009, 100:1048-1054.
26. Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010, 2010:162-177.
27. Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg 2005, 242:1-6.
28. Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol 2006, 24:337-344.
29. Martelli G, Miceli R, Daidone MG, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol 2011, 18:125-133.
30. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
31. Straver ME, Meijnen P, van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010, 28:731-737.
32. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
33. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004, 351:971-977.
34. Hughes K, Schnaper L, Cirrincione C, et al. Lumpectomy plus tamoxifen with or without irradiation in women aged 70 or older with early breast cancer. Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 507.
35. Mannino M, Yarnold JR Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld?. Radiother Oncol 2009, 90:14-22.
36. Williams LJ, Kunkler IH, King CC, Jack W, van der Pol M A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial. Health Technol Assess 2011, 15:1-57.
37. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008, 9:331-341.
38. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371:1098-1107.
39. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362:513-520.
40. Kirova YM, Campana F, Savignoni A, et al. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75:76-81.
41. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010, 376:91-102.
42. Veronesi U, Orecchia R, Luini A, et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat 2010, 124:141-151.
43. Macaskill EJ, Renshaw L, Dixon JM Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist 2006, 11:1081-1088.
44. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12:1527-1532.
45. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23:5108-5116.
46. Hind D, Wyld L, Reed MW Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review. Br J Cancer 2007, 96:1025-1029.
47. Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst 2011, 103:1363-1372.
48. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
49. Biganzoli L, Licitra S, Claudino W, et al. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients-a jungle?. Eur J Cancer 2007, 43:2270-2278.
50. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008, 26:1956-1964.
51. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008, 26:1972-1979.
52. Phillips KA, Ribi K, Sun Z, et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010, 19:388-395.
53. Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010, 21:1657-1680.
54. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360:2055-2065.
55. Garg P, Rana F, Gupta R, Buzaianu EM, Guthrie TH Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients. Breast J 2009, 15:404-408.
56. Loibl S, von Minckwitz G, Harbeck N, et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 2008, 10:R77.
57. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009, 27:1177-1183.
58. Freyer G, Campone M, Peron J, et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Crit Rev Oncol Hematol 2011, 80:466-473.
59. Crivellari D, Aapro M, Leonard R, et al. Breast cancer in the elderly. J Clin Oncol 2007, 25:1882-1890.
60. Rousseau F, Retornaz F, Joly F, et al. Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO). Crit Rev Oncol Hematol 2010, 76:71-78.
61. Brunello A, Monfardini S, Crivellari D, et al. Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (> 70 years). Proc Am Soc Clin Oncol 2008, 26. abstr 1096.
62. Lapatinib product insert GlaxoSmithKline, (accessed Feb 7, 2012). http://us.gsk.com/products/assets/us_tykerb.pdf.
63. Crown JP, Burris HA, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008, 112:317-325.
64. Vogel CL, Cobleigh MA, Tripathy D, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001, 61:37-42.
65. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
66. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
67. O'Shaughnessy J, Miles D, Gray R, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 1005.
68. Biganzoli L, Di Vincenzo E, Jiang Z, et al. First-line bevacizumab-containing therapy for breast cancer: results in patients aged >=70 years treated in the ATHENA study. Ann Oncol 2012, 23:111-118.
69. Major P Preserving functional independence in elderly patients with cancer-associated bone disease: the role of zoledronic acid. Future Medicine 2009, 5:151-164.
70. Launay-Vacher V, Chatelut E, Lichtman SM, Wildiers H, Steer C, Aapro M Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007, 18:1314-1321.
71. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007, 43:14-34.
72. Partridge AH, Archer L, Kornblith AB, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010, 28:2418-2422.
73. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008, 26:549-555.
74. Lück H, Hadji P, Harbeck N, et al. 24-month follow-up from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 526.
75. Pinquart M, Duberstein PR Information needs and decision-making processes in older cancer patients. Crit Rev Oncol Hematol 2004, 51:69-80.
76. Bastiaens H, Van Royen P, Pavlic DR, Raposo V, Baker R Older people's preferences for involvement in their own care: a qualitative study in primary health care in 11 European countries. Patient Educ Couns 2007, 68:33-42.
77. Enger SM, Thwin SS, Buist DS, et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 2006, 24:4377-4383.
78. Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002, 95:989-996.
79. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003, 21:2268-2275.
80. Repetto L, Piselli P, Raffaele M, Locatelli C Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. Eur J Cancer 2009, 45:374-383.
81. Giacalone A, Talamini R, Spina M, Fratino L, Spazzapan S, Tirelli U Can the caregiver replace his/her elderly cancer patient in the physician-patient line of communication?. Support Care Cancer 2008, 16:1157-1162.
82. Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol 2010, 73:246-254.
83. Harlan LC, Zujewski JA, Goodman MT, Stevens JL Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival. Cancer 2010, 116:3558-3568.
84. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010, 28:2114-2122.
85. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005, 104:2359-2364.
86. Mauras N, O'Brien KO, Klein KO, Hayes V Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000, 85:2370-2377.